摘要
目的:观察降糖消脂片对肥胖模型大鼠Lee's指数、血脂及病理形态学等指标的影响,研究其药理作用。方法:采用SD大鼠,高脂饲料喂养18周,造成肥胖大鼠模型。普通饲料组为对照组,高脂饲料组分为模型组、二甲双胍组(0.3 g/kg)、辛伐他汀组(4 mg/kg)、降糖消脂片高、中、低剂量组(8、4、2 g生药/kg)。12只/组,连续灌胃给药8周,1次/d。观察给药期间大鼠体质量及摄食量的变化,测定Lee's指数、血脂及游离脂肪酸(FFA),并对肝脏和脂肪进行形态学观察。结果:给药8周后与模型组比较,降糖消脂片高、中剂量组大鼠肥胖症状明显减轻、体质量明显降低(P<0.05~0.01);Lee's指数明显降低(P<0.05~0.01)、总胆固醇(TC)和低密度脂蛋白胆固醇(LDL-C)明显降低(P<0.05);高剂量组高密度脂蛋白胆固醇(HDL-C)明显升高(P<0.01)、TC/HDL-C有所降低(P<0.05);低剂量组极低密度脂蛋白胆固醇(VLDL-C)有所降低(P<0.05);降糖消脂片各剂量组FFA明显降低(P<0.01);病理结果显示:降糖消脂片各剂量组的肝脏和脂肪组织病理变化与模型组比较,有不同程度的减轻;降糖消脂片各剂量组肝脏脂肪变性有明显改善(P<0.05~0.01)。结论 :降糖消脂片有明显减重、降脂、改善肝脏脂肪变性的作用,其机制可能与降低FFA,改善脂代谢紊乱有关。
Objective： To observe the effects of Jiangtang Xiaozhi Pills（ JTXZP） on Lee＇s index,blood lipid and pathological morphology of obesity rat models and to study its pharmacology. Methods： SD rats were fed for 18 weeks with high-fat diet to induce rat model. The animals were divided into 7 groups of normal control group（ common diet）,model group,metformin group（ 0. 3 g/kg）,simvastatin group（ 4 mg/kg） and high-dose,middle-dose and low-dose JTXZP groups（ 2 g,4 g and 8 g crude drug/kg）,respectively,with 12 rats in each group. The duration of treatment was 8 weeks,1 time/day. The changes in body weight（ BW）and dietary intake were observed during the treatment time,and Lee＇ s index,blood lipid and free fat acid（ FFA） were tested. The morphological observation was conducted on the liver and the fat. Results： Compared with the model group after 8 weeks of drug administration,the symptoms of obesity were significantly improved,the body weight（ P〈0. 05 - 0. 01）,Lee＇ s index（ P〈0. 05- 0. 01）,total cholesterol（ TC）,low density lipoprotein-cholesterol（ LDL-C） were all decreased significantly（ P〈0. 05）. High density lipoprotein cholesterol（ HDL-C） in high-dose group increased significantly（ P 0. 01）,and TC/HDL-C decreased（ P〈0. 05）. Low-dose group LDL cholesterol（ VLDL-C） decreased（ P〈0. 05）. FFA values were decreased in all three dose of JTXZP groups（ P〈 0. 01）. Pathology results showed that there was improvement of different levels in the liver and fat at all dose of groups of JTXZP. Each dosage group of JTXZP had a significant improvement in hepatic steatosis（ P〈0. 05）. Conclusion：JTXZP could decrease the body weight,blood fat and improve the hepatic steatosis. Its mechanism may be related to reducing FFA and improving lipid metabolic disorder.
作者
金龙
葛争艳
董小霞
杨斌
李宏坤
郭宇洁
任烨
洪晓华
王杨慧
刘建勋
Jin Long;Ge Zhengyan;Dong Xiaoxia;Yang Bin;Li Hongkun;Guo Yujie;Ren Ye;Hong Xiaohua;Wang Yangyui;Liu Jianxun(Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing Key Laboratory of Chinese Materia Medica, Beijing 100091, China)
出处
《世界中医药》
CAS
2018年第1期5-11,共7页
World Chinese Medicine
基金
国家重点基础研究发展计划(973计划)项目(2015CB554405)
国家科技重大专项“重大新药创制”(2017ZX09301018)
